Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

11 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - MAGE-A3 Expression Test; Tumor Sample (For Re-Test); MAGE-A3 Expression Re-Test; Prior Surgery; Prior Therapy (Annex Report 2 Final)

- 17/09/2021 - 1 Formulaire, 9 Groupes Item, 51 Eléments de données, 1 Langue
Groupes Item: Administrative, MAGE-A3 Expression Test, Tumor Sample (For Re-Test), MAGE-A3 Expression Re-Test, Prior Surgery, Prior Surgery Type, Prior Surgery, Prior Therapy, Prior treatment with systemic immunosuppressants
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - MAGE-A3 Expression Test; Tumor Sample (For Re-Test); MAGE-A3 Expression Re-Test; Prior Surgery; Prior Therapy

- 17/09/2021 - 1 Formulaire, 8 Groupes Item, 50 Eléments de données, 1 Langue
Groupes Item: Administrative, MAGE-A3 Expression Test, Tumor Sample (For Re-Test), MAGE-A3 Expression Re-Test, Prior Surgery, Prior Surgery Type, Prior Therapy, Prior treatment with systemic immunosuppressants
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Radiotherapy; Local Surgery (Report Final and Annex Report 2 Final)

- 30/10/2020 - 1 Formulaire, 5 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Administrative, Radiotherapy, Radiotherapy , Local Surgery, Local Surgery
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Breast Cancer Swedish National Quality Registry - Surgery

- 18/01/2018 - 1 Formulaire, 5 Groupes Item, 60 Eléments de données, 2 Langues
Groupes Item: National Quality Register for Breast Cancer, Surgery, Surgery, Pathology, Postoperative Assessment, Responsible Hospital / deparment for treatment and Follow-up
Description of registry: The aim of the National Quality Registry for Breast Cancer is to: -in an objective and standardised manner, monitor the continuum of care from diagnosis to any recurrence and death -enable the identification of regional differences -collectively relate to current guidelines and quality targets set by specialist associations and the National Board of Health and Welfare -facilitate research and developments in breast cancer. Surgery Source: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/dokument/ Facts Owner: Kerstin Sandelin surgeon, Karolinska University Hospital, Solna kerstin.sandelin@sll.se

UKHD - Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Verlaufsangaben

- 09/03/2022 - 10 Formulaires, 3 Groupes Item, 38 Eléments de données, 1 Langue
Groupes Item: Verlaufsangaben, Präoperative Vorbereitung - Checkliste, OP und Verlauf
Routinedokumentation der Universitäts-Frauenklinik, Sektion Senologie Verlaufsblatt - Mamma Carcinom - Multimodale Brustdiagnostik. Sektionsleiter Senologie: Prof. Dr. med. Jörg Heil, MHBA

Empfehlung des postoperativen Tumorboards

1 Groupe Item 26 Eléments de données

Poststationäre Ergänzungen

1 Groupe Item 2 Eléments de données

Pathologie

3 Groupes Item 121 Eléments de données

Procedere

1 Groupe Item 27 Eléments de données

Prätherapeutische und präoperative Konferenz(en)

5 Groupes Item 46 Eléments de données

Allgemeines: Personalien, Diagnose, Therapie und Anamnese

3 Groupes Item 43 Eléments de données

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 23/08/2019 - 1 Formulaire, 13 Groupes Item, 48 Eléments de données, 1 Langue
Groupes Item: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Q181 16 Operation University Hospital Muenster (UKM) Subform

- 13/11/2016 - 1 Formulaire, 1 Groupe Item, 7 Eléments de données, 1 Langue
Groupe Item: Surgery
Hospital Routine Documentation Subform at the University Hospital Muenster. Original Form name: Q181 16 Operation

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course -- Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 02/09/2019 - 1 Formulaire, 9 Groupes Item, 41 Eléments de données, 1 Langue
Groupes Item: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 3 Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 01/09/2019 - 1 Formulaire, 9 Groupes Item, 40 Eléments de données, 1 Langue
Groupes Item: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 2 Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 30/08/2019 - 1 Formulaire, 9 Groupes Item, 40 Eléments de données, 1 Langue
Groupes Item: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Course 1 Prior to next Course (Day 25 - 28) - Vital Signs; Tumor Marker (CA-125); Laboratory Tests; Lesion Assessment Record

- 29/08/2019 - 1 Formulaire, 9 Groupes Item, 40 Eléments de données, 1 Langue
Groupes Item: Administrative, Vital Signs, Tumor Marker (CA-125), Laboratory Tests - Haematology, Laboratory Tests - Haematology , Laboratory Tests - Chemistry, Laboratory Tests - Chemistry , Lesion Assessment, Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial